Clinical Trial: Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units
Brief Summary: The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10 score etc.); Efficacy of Tygacil under usual care conditions (cure rate).
Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Wyeth is now a wholly owned subsidiary of Pfizer
Dates:
Date Received: May 31, 2007
Date Started: February 2006
Date Completion:
Last Updated: September 25, 2009
Last Verified: September 2009